[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Sybron Dental Specialties\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":54},{"warningLetters":4,"total":53},[5,31],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},898,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-05-20T04:00:00Z\">05\u002F20\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-05-08T04:00:00Z\">05\u002F08\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicrospecialties-llc-707614-05082025\">Microspecialties, LLC\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Gaston S. Levesque\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Microspecialties, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>430 Smith Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Middletown\u003C\u002Fspan>, \u003Cspan>CT\u003C\u002Fspan> \u003Cspan>06457\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:steven.levesque@microspecialties.com\"> steven.levesque@microspecialties.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 707614\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>May 8, 2025\u003C\u002Fp>\u003Cp>Dear Gaston S. Levesque:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Middletown, CT, from January 14, 2025, through February 18, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm contract manufactures Class I and II ophthalmic surgical devices such as sterile I-PACK injection kits, punctum plugs, and microkeratome blades. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Rick Brinsmade, Quality Assurance and Regulatory Affairs (QA\u002FRA) Manager, dated March 4, 2025 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish and maintain procedures for finished device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR 820.80(d).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement section 6.13 of your “Sterilization Process Control” procedure (QA-0041; Rev 3; Effective: 1\u002F27\u002F23) which requires release of sterile products to inventory via Form 0070 once accompanying dosimetry records and certificates of processing (COPs) are received back from the contract sterilizer. For example, you stated that Form 0070 was never utilized to release \u003Cstrong>(b)(4)\u003C\u002Fstrong> boxes of I-PACK injection kits (Lot #: P62764979R, P63044983R, P62764965R and P62764970R) into inventory because you fabricated the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization COPs (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) as if they originated from the customer-approved contract sterilizer. Subsequently, on 03\u002F21\u002F24, your Director of Quality Assurance released the above nonconforming lots of I-PACK injection kits, which are intended for administration of intravitreal injections during eye surgery, as sterile to your customer on 3\u002F12\u002F24 despite never shipping these products to the customer-approved contract sterilizer (or elsewhere) for sterilization. This event resulted in a Class II recall RES 94794 initiated by your firm on 6\u002F5\u002F24 followed up by a Class I recall by your customer on \u003Cstrong>(b)(4)\u003C\u002Fstrong> under RES \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>The adequacy of the response dated 3\u002F4\u002F25 cannot be determined at this time. Under CAR # 1288 (2\u002F20\u002F25) opened to address the failure to follow QA-0041, you reference CAR # 1261 (5\u002F31\u002F24) for the root cause which pointed to limited resources, lack of effectiveness of training, storage of product in a non-routine location, and lack of \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization labels. Corrective actions included notification of the nonconforming lots to your customer upon discovery of the error; replacement of your Director of Quality Assurance with a new Quality Assurance and Regulatory Affairs Manager; addition of \u003Cstrong>(b)(4)\u003C\u002Fstrong> exposure indication dots to shipping cartons; update of Form 0070 to include verification of \u003Cstrong>(b)(4)\u003C\u002Fstrong> indicator dot color changes; update of QA-0041 to restrict product release to QA, President, or Administrative Assistant; update the training procedure (QA-0019) to include effectiveness tests, including a test for sterilization processes; and retrospective review of sterilization and release documentations to verify accuracy. Under CAR # 1289 (2\u002F20\u002F25) opened to address release of nonconforming product, you also reference the root cause(s) and several of the corrective actions above under CAR # 1261 and note additional completed actions which included the requirement for \u003Cstrong>(b)(4)\u003C\u002Fstrong> irradiation exposure dots on shipping cartons and process specifications for your new contract sterilizer in QA-0041; addition of integrity requirements to the document, part number, and data control procedure (QA-0020); and a new code of conduct and ethics procedure (QA-0099) for which all employees completed training. By 6\u002F1\u002F25, you plan to also add irradiation exposure dots to each individual carton of trays and microkeratome blades. Please provide updates on the progress of these corrective actions and corrections, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically:\u003C\u002Fp>\u003Cp>a. You failed to implement sections 5.1.2 and 5.2.1 of your “Process Validation” procedure (QA-0063; Effective: 11\u002F8\u002F23) which requires that Operations (with input from Quality) determine “***\u003Cem>if re-validation is needed for changes to validation manufacturing processes\u003C\u002Fem>***” and that Quality “***\u003Cem>Reviews and approves the assessments of validation needs and revalidation determinations\u003C\u002Fem>***,” respectively. For example, you authorized the release of lots \u003Cstrong>(b)(4)\u003C\u002Fstrong> on 9\u002F4\u002F24; \u003Cstrong>(b)(4)\u003C\u002Fstrong> on 10\u002F14\u002F24; and \u003Cstrong>(b)(4)\u003C\u002Fstrong> on 11\u002F19\u002F24, containing medical devices, such as punctum plugs, customized injection trays, microkeratome blades, microkeratome tubing, and ophthalmic convenience kits, for distribution without documented justification for why a revalidation was not required, prior to switching to a new contract sterilizer for \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization of such devices on 3\u002F19\u002F24.\u003C\u002Fp>\u003Cp>b. You failed to implement sections 1.0 and 2.0 of your “Process Validation” procedure (QA-0063; Effective: 11\u002F8\u002F23) which require validations of processes related to inventory items such as “***\u003Cem>a component, material, assembly, packaging, and labeling that is part or will become part of the finished medical device including the finished medical device\u003C\u002Fem>***.” For example, you did not conduct a validation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection method outlined in section 6.1.2 of the “Seal Inspection” procedure (QA-0042; Effective: 6\u002F30\u002F24) for testing the seal integrity of sterile pouches containing Microkeratome Blades, to ensure that manufacturing employees are able to repeatably and reproducibly able to detect conforming and nonconforming seal pouches with a high degree of assurance as a part of finished device acceptance. These devices are indicated for use during LASIK surgery to shave tissue from sections of the cornea for a lamellar (partial thickness) transplant.\u003C\u002Fp>\u003Cp>The response dated 3\u002F4\u002F25 is not adequate. Under CAR # 1290 (2\u002F20\u002F25) initiated to address release of sterile products prior to conducting a revalidation for the new contract sterilizer, you state that management did not believe that a revalidation was required because the new contract \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilizer was able to sterilize the product with the specified dose mapping and dose audits and bioburden testing continued. In addition, you point out that your newly hired QA\u002FRA manager determined that a retrospective validation was required such that a comprehensive validation was conducted and formally approved on 12\u002F16\u002F24. However, there were no corrective actions identified to address the primary issue which is that you did not follow your procedure to review and approve your decision not to revalidate the sterilization process at the time these products were released for distribution.\u003C\u002Fp>\u003Cp>With regards to the lack of test method validation for the seal integrity inspection, you state that you will write a formal process adoption by analyzing the data outputs from the seal validations by 5\u002F1\u002F25. However, there were no corrective actions identified to review whether any other test methods require process validations to demonstrate that that you are able to consistently detect conforming and nonconforming product with a high degree of assurance. Therefore, please provide a response on how you plan to address the above deficiencies.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to ensure that sampling plans are written and based on a valid statistical rationale when used, as required by 820.250(b).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you acknowledged there was no statistical rationale documented for the sampling plan in section 6.1.2 of the “Seal Inspection” procedure (QA-0042; Effective: 6\u002F30\u002F24) to inspect the first \u003Cstrong>(b)(4)\u003C\u002Fstrong> pouches for seal integrity.\u003C\u002Fp>\u003Cp>The response dated 3\u002F4\u002F25 is not adequate. Under CAR # 1290 (2\u002F20\u002F25) initiated to address the lack of test method validation for the seal integrity inspection as well as failure to provide statistically supported evidence when sampling, you state that you will write a formal process adoption by analyzing the data outputs from the seal validations by 5\u002F1\u002F25. However, there were no corrective actions identified to address the concerns relating to lack of valid statistical rationale for the sampling plan employed during sealing inspections of sterile pouches. Therefore, please provide a response on how you plan to address the above deficiencies.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 707614” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC: Rick Brinsmade, QA\u002FRA Manager, rick@pro-paks.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nGaston S. Levesque\n\nRecipient Title\n\nPresident and CEO\n\nMicrospecialties, LLC\n\n430 Smith Street\n\nMiddletown, CT 06457\n\nUnited States\n\nsteven.levesque@microspecialties.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 707614\nMay 8, 2025\nDear Gaston S. Levesque:\nDuring an inspection of your firm located in Middletown, CT, from January 14, 2025, through February 18, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm contract manufactures Class I and II ophthalmic surgical devices such as sterile I-PACK injection kits, punctum plugs, and microkeratome blades. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Rick Brinsmade, Quality Assurance and Regulatory Affairs (QA\u002FRA) Manager, dated March 4, 2025 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures for finished device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR 820.80(d).\nSpecifically, you failed to implement section 6.13 of your “Sterilization Process Control” procedure (QA-0041; Rev 3; Effective: 1\u002F27\u002F23) which requires release of sterile products to inventory via Form 0070 once accompanying dosimetry records and certificates of processing (COPs) are received back from the contract sterilizer. For example, you stated that Form 0070 was never utilized to release (b)(4) boxes of I-PACK injection kits (Lot #: P62764979R, P63044983R, P62764965R and P62764970R) into inventory because you fabricated the (b)(4) sterilization COPs ((b)(4) and (b)(4)) as if they originated from the customer-approved contract sterilizer. Subsequently, on 03\u002F21\u002F24, your Director of Quality Assurance released the above nonconforming lots of I-PACK injection kits, which are intended for administration of intravitreal injections during eye surgery, as sterile to your customer on 3\u002F12\u002F24 despite never shipping these products to the customer-approved contract sterilizer (or elsewhere) for sterilization. This event resulted in a Class II recall RES 94794 initiated by your firm on 6\u002F5\u002F24 followed up by a Class I recall by your customer on (b)(4) under RES (b)(4).\nThe adequacy of the response dated 3\u002F4\u002F25 cannot be determined at this time. Under CAR # 1288 (2\u002F20\u002F25) opened to address the failure to follow QA-0041, you reference CAR # 1261 (5\u002F31\u002F24) for the root cause which pointed to limited resources, lack of effectiveness of training, storage of product in a non-routine location, and lack of (b)(4) sterilization labels. Corrective actions included notification of the nonconforming lots to your customer upon discovery of the error; replacement of your Director of Quality Assurance with a new Quality Assurance and Regulatory Affairs Manager; addition of (b)(4) exposure indication dots to shipping cartons; update of Form 0070 to include verification of (b)(4) indicator dot color changes; update of QA-0041 to restrict product release to QA, President, or Administrative Assistant; update the training procedure (QA-0019) to include effectiveness tests, including a test for sterilization processes; and retrospective review of sterilization and release documentations to verify accuracy. Under CAR # 1289 (2\u002F20\u002F25) opened to address release of nonconforming product, you also reference the root cause(s) and several of the corrective actions above under CAR # 1261 and note additional completed actions which included the requirement for (b)(4) irradiation exposure dots on shipping cartons and process specifications for your new contract sterilizer in QA-0041; addition of integrity requirements to the document, part number, and data control procedure (QA-0020); and a new code of conduct and ethics procedure (QA-0099) for which all employees completed training. By 6\u002F1\u002F25, you plan to also add irradiation exposure dots to each individual carton of trays and microkeratome blades. Please provide updates on the progress of these corrective actions and corrections, including any supporting evidence.\n2. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\nSpecifically:\na. You failed to implement sections 5.1.2 and 5.2.1 of your “Process Validation” procedure (QA-0063; Effective: 11\u002F8\u002F23) which requires that Operations (with input from Quality) determine “***if re-validation is needed for changes to validation manufacturing processes***” and that Quality “***Reviews and approves the assessments of validation needs and revalidation determinations***,” respectively. For example, you authorized the release of lots (b)(4) on 9\u002F4\u002F24; (b)(4) on 10\u002F14\u002F24; and (b)(4) on 11\u002F19\u002F24, containing medical devices, such as punctum plugs, customized injection trays, microkeratome blades, microkeratome tubing, and ophthalmic convenience kits, for distribution without documented justification for why a revalidation was not required, prior to switching to a new contract sterilizer for (b)(4) sterilization of such devices on 3\u002F19\u002F24.\nb. You failed to implement sections 1.0 and 2.0 of your “Process Validation” procedure (QA-0063; Effective: 11\u002F8\u002F23) which require validations of processes related to inventory items such as “***a component, material, assembly, packaging, and labeling that is part or will become part of the finished medical device including the finished medical device***.” For example, you did not conduct a validation of the (b)(4) inspection method outlined in section 6.1.2 of the “Seal Inspection” procedure (QA-0042; Effective: 6\u002F30\u002F24) for testing the seal integrity of sterile pouches containing Microkeratome Blades, to ensure that manufacturing employees are able to repeatably and reproducibly able to detect conforming and nonconforming seal pouches with a high degree of assurance as a part of finished device acceptance. These devices are indicated for use during LASIK surgery to shave tissue from sections of the cornea for a lamellar (partial thickness) transplant.\nThe response dated 3\u002F4\u002F25 is not adequate. Under CAR # 1290 (2\u002F20\u002F25) initiated to address release of sterile products prior to conducting a revalidation for the new contract sterilizer, you state that management did not believe that a revalidation was required because the new contract (b)(4) sterilizer was able to sterilize the product with the specified dose mapping and dose audits and bioburden testing continued. In addition, you point out that your newly hired QA\u002FRA manager determined that a retrospective validation was required such that a comprehensive validation was conducted and formally approved on 12\u002F16\u002F24. However, there were no corrective actions identified to address the primary issue which is that you did not follow your procedure to review and approve your decision not to revalidate the sterilization process at the time these products were released for distribution.\nWith regards to the lack of test method validation for the seal integrity inspection, you state that you will write a formal process adoption by analyzing the data outputs from the seal validations by 5\u002F1\u002F25. However, there were no corrective actions identified to review whether any other test methods require process validations to demonstrate that that you are able to consistently detect conforming and nonconforming product with a high degree of assurance. Therefore, please provide a response on how you plan to address the above deficiencies.\n3. Failure to ensure that sampling plans are written and based on a valid statistical rationale when used, as required by 820.250(b).\nSpecifically, you acknowledged there was no statistical rationale documented for the sampling plan in section 6.1.2 of the “Seal Inspection” procedure (QA-0042; Effective: 6\u002F30\u002F24) to inspect the first (b)(4) pouches for seal integrity.\nThe response dated 3\u002F4\u002F25 is not adequate. Under CAR # 1290 (2\u002F20\u002F25) initiated to address the lack of test method validation for the seal integrity inspection as well as failure to provide statistically supported evidence when sampling, you state that you will write a formal process adoption by analyzing the data outputs from the seal validations by 5\u002F1\u002F25. However, there were no corrective actions identified to address the concerns relating to lack of valid statistical rationale for the sampling plan employed during sealing inspections of sterile pouches. Therefore, please provide a response on how you plan to address the above deficiencies.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 707614” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC: Rick Brinsmade, QA\u002FRA Manager, rick@pro-paks.com","Microspecialties, LLC","microspecialties-llc-707614-05082025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicrospecialties-llc-707614-05082025","2026-10-26T08:09:24.836404+00:00","Warning Letter","Issued","2025-05-20","707614","Medical Devices","Gaston S. Levesque","2026-08-19T16:46:07.915+00:00","VIA Electronic Mail","2025-05-08",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},1096,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2025-01-14T14:20:00Z\">01\u002F14\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-23T05:00:00Z\">12\u002F23\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgeorge-food-specialties-inc-697738-12232024\">By George Food Specialties Inc.\u003C\u002Fa>","Division of Northern Border Imports","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Susan L. Walsh\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>By George Food Specialties Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1149 State Route 50\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ballston Lake\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>12019-1922\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Northern Border Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 23, 2024\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS # 697738\u003C\u002Fp>\u003Cp>Dear Ms. Walsh:\u003C\u002Fp>\u003Cp>On 11\u002F4\u002F2024-11\u002F25\u002F2024, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of By George Food Specialties Inc. located at 1149 State Route 50. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on 11\u002F25\u002F2024.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import. Including each of the following foods:\u003C\u002Fp>\u003Cul>\u003Cli>Mayonnaise imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Mayonnaise imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Hot Sauce imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>\u003C\u002Fp>\u003Cp>In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Alyssa Wenke, Compliance Officer, Division of Northern Border Imports. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Alyssa Wenke via email at Alyssa.Wenke@fda.hhs.gov. Please reference CMS # 697738 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Keith J. Jasukaitis\u003Cbr>Program Division Director\u003Cbr>Division of Northern Border Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMs. Susan L. Walsh\n\nBy George Food Specialties Inc.\n\n1149 State Route 50\n\nBallston Lake, NY 12019-1922\n\nUnited States\n\n(b)(6)\n\nIssuing Office:\n\nDivision of Northern Border Imports\n\nUnited States\n\nDecember 23, 2024\nWARNING LETTER\nRe: CMS # 697738\nDear Ms. Walsh:\nOn 11\u002F4\u002F2024-11\u002F25\u002F2024, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of By George Food Specialties Inc. located at 1149 State Route 50. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on 11\u002F25\u002F2024.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import. Including each of the following foods:\nMayonnaise imported from (b)(4) located in (b)(4)\nMayonnaise imported from (b)(4) located in (b)(4)\nHot Sauce imported from (b)(4) located in (b)(4)\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\nIn addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Alyssa Wenke, Compliance Officer, Division of Northern Border Imports. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Alyssa Wenke via email at Alyssa.Wenke@fda.hhs.gov. Please reference CMS # 697738 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nKeith J. Jasukaitis\nProgram Division Director\nDivision of Northern Border Imports","By George Food Specialties Inc.","george-food-specialties-inc-697738-12232024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgeorge-food-specialties-inc-697738-12232024","2026-10-26T08:08:45.641765+00:00","2025-01-14","697738","Food & Beverages","Ms. Susan L. Walsh","2026-08-19T17:04:39.444+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2024-12-23",2,{"510k":55,"classification":56,"enforcement":57,"event":58,"event_backfill":59,"pma":60,"warning_letter":61},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]